<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Multi-Axial Compensatory Oncogenic Process Theory in Driver-Negative Lung Adenocarcinoma - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-17</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-17</p>
                <p><strong>Name:</strong> Multi-Axial Compensatory Oncogenic Process Theory in Driver-Negative Lung Adenocarcinoma</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of what drives lung adenocarcinomas without known RTK/RAS/RAF pathway driver alterations, based on the following results.</p>
                <p><strong>Description:</strong> This theory posits that lung adenocarcinomas lacking classical RTK/RAS/RAF pathway driver alterations—so-called 'driver-negative' tumors—are sustained by functionally compensatory mechanisms falling in four major axes: (a) alternative non-canonical genetic drivers (including rare oncogenes, gene fusions, copy-number alterations), (b) epigenetic and transcriptomic deregulation (such as CpG island methylator phenotype, chromatin/splicing factor mutations, large methylation or expression blocks), (c) endogenous and exogenous mutagenic processes fueling subclonal evolution (e.g., APOBEC, inefficient repair of methyl-cytosine deamination), and (d) microenvironmental or immune escape mechanisms. The convergence and pairing of these processes collectively substitute for canonical oncogenic signaling, producing overlapping phenotypic outputs (cell proliferation, immune evasion, etc.) that sustain tumorigenesis and progression despite heterogeneous molecular origins.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-4.1-2025-04-14</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Functional Substitution of Canonical Signaling by Diverse Alternative Processes in RTK/RAS/RAF-Negative LUAD</h3>
            <p><strong>Statement:</strong> Lung adenocarcinomas lacking canonical RTK/RAS/RAF pathway driver alterations can achieve oncogenic transformation and progression through functionally equivalent alternative processes—namely (1) rare/cryptic mutations or gene fusions in non-canonical oncogenes (e.g., NF1, RIT1, MET exon 14 skipping, NTRK1, RET, ALK/ROS1 fusions, MGA, ZKSCAN1, chromatin/splicing factor mutations, etc.), (2) regional or whole-genome copy number alterations—including both focal oncogene amplifications (FGFR1, FUS, NSD1, MYC, ERBB2, MET, TERT), tumor suppressor deletions (RB1, CDKN2A, WRN, PTEN), or arm-level gains/losses—(3) epigenetic silencing/signature changes (CIMP-high, extensive promoter hypermethylation, block methylation/acetylation, global chromatin deregulation), and (4) microenvironmental or immune-driven selection (HLA LOH, B2M mutations, neoantigen methylation, stromal interactions, paracrine signaling), with these processes acting alone or in modular combinations to activate core oncogenic outputs (MAPK, PI3K, mTOR, WNT pathways, immune evasion, cell-cycle deregulation, etc.).</p>
            <p><strong>Domain/Scope:</strong> Applies to human lung adenocarcinomas where there are no detectable canonical RTK/RAS/RAF driver alterations (including EGFR, KRAS, BRAF, ALK, RET, ROS1, and canonical PI3K/AKT pathway mutations/fusions), irrespective of smoking status, age, or early/late-stage disease, and across all major global populations, provided comprehensive profiling is performed to exclude recognized canonical events.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>A small subset of tumors remain without any detectable plausible drivers or compensatory processes even with multi-omic profiling ('orphan', 'pan-negative' cases).</li>
                <li>In some tumors, these compensatory mechanisms may work in additive or parallel rather than strictly mutually exclusive fashion (for example, a tumor may have both an epigenetic alteration and a fusion or copy-number change).</li>
                <li>Sampling artifacts may render some tumors 'driver-negative' when in fact subclonal or localized canonical drivers are present.</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Diverse alternative genetic events—including rare mutations/fusions in NF1, RIT1, MET exon 14 skipping, NTRK1/RET/ROS1 fusions, MGA, ZKSCAN1, ASEF, NOTCH2, LMTK2, etc.—occur in 'driver-negative' LUADs, and these events are found at statistically significant frequencies in numerous cohorts. <a href="../results/extraction-result-39.html#e39.0" class="evidence-link">[e39.0]</a> <a href="../results/extraction-result-39.html#e39.2" class="evidence-link">[e39.2]</a> <a href="../results/extraction-result-39.html#e39.3" class="evidence-link">[e39.3]</a> <a href="../results/extraction-result-103.html#e103.2" class="evidence-link">[e103.2]</a> <a href="../results/extraction-result-41.html#e41.0" class="evidence-link">[e41.0]</a> <a href="../results/extraction-result-40.html#e40.0" class="evidence-link">[e40.0]</a> <a href="../results/extraction-result-115.html#e115.0" class="evidence-link">[e115.0]</a> <a href="../results/extraction-result-42.html#e42.0" class="evidence-link">[e42.0]</a> <a href="../results/extraction-result-34.html#e34.0" class="evidence-link">[e34.0]</a> <a href="../results/extraction-result-37.html#e37.4" class="evidence-link">[e37.4]</a> <a href="../results/extraction-result-33.html#e33.0" class="evidence-link">[e33.0]</a> <a href="../results/extraction-result-114.html#e114.1" class="evidence-link">[e114.1]</a> <a href="../results/extraction-result-39.html#e39.1" class="evidence-link">[e39.1]</a> <a href="../results/extraction-result-39.html#e39.5" class="evidence-link">[e39.5]</a> </li>
    <li>Copy-number alterations, including focal amplifications or deletions of FGFR1, FUS, NSD1, TERT, MYC, LETM2, WHSC1L1, BRF2, GOLPH3, TRIO, and arm-level or regional gains/losses (e.g., 7p/7q, 5p, 8q, 13q losses of RB1), recurrently occur in subsets of tumors lacking canonical drivers. Subclonal and regional CNA events expand driver diversity. <a href="../results/extraction-result-115.html#e115.0" class="evidence-link">[e115.0]</a> <a href="../results/extraction-result-103.html#e103.0" class="evidence-link">[e103.0]</a> <a href="../results/extraction-result-103.html#e103.2" class="evidence-link">[e103.2]</a> <a href="../results/extraction-result-103.html#e103.1" class="evidence-link">[e103.1]</a> <a href="../results/extraction-result-103.html#e103.6" class="evidence-link">[e103.6]</a> <a href="../results/extraction-result-44.html#e44.0" class="evidence-link">[e44.0]</a> <a href="../results/extraction-result-103.html#e103.3" class="evidence-link">[e103.3]</a> <a href="../results/extraction-result-41.html#e41.8" class="evidence-link">[e41.8]</a> <a href="../results/e41.10.html#e41.10" class="evidence-link">[e41.10]</a> <a href="../results/extraction-result-115.html#e115.7" class="evidence-link">[e115.7]</a> <a href="../results/extraction-result-106.html#e106.0" class="evidence-link">[e106.0]</a> <a href="../results/extraction-result-38.html#e38.0" class="evidence-link">[e38.0]</a> <a href="../results/extraction-result-35.html#e35.6" class="evidence-link">[e35.6]</a> </li>
    <li>Epigenetic alterations, including CIMP-high methylator phenotype, large methylation/acetylation blocks (RBBP7, YEATS2), frequent mutations in chromatin/splicing factor genes (ARID1A, SMARCA4, SETD2, U2AF1, RBM10, spliceosome genes), and other DNA methylation signatures, are recurrent in tumor subgroups without canonical proliferative signaling. <a href="../results/extraction-result-44.html#e44.3" class="evidence-link">[e44.3]</a> <a href="../results/extraction-result-36.html#e36.3" class="evidence-link">[e36.3]</a> <a href="../results/extraction-result-36.html#e36.7" class="evidence-link">[e36.7]</a> <a href="../results/extraction-result-36.html#e36.4" class="evidence-link">[e36.4]</a> <a href="../results/extraction-result-36.html#e36.2" class="evidence-link">[e36.2]</a> <a href="../results/extraction-result-31.html#e31.0" class="evidence-link">[e31.0]</a> <a href="../results/extraction-result-31.html#e31.2" class="evidence-link">[e31.2]</a> <a href="../results/extraction-result-31.html#e31.1" class="evidence-link">[e31.1]</a> <a href="../results/extraction-result-40.html#e40.8" class="evidence-link">[e40.8]</a> <a href="../results/extraction-result-39.html#e39.8" class="evidence-link">[e39.8]</a> <a href="../results/extraction-result-44.html#e44.4" class="evidence-link">[e44.4]</a> </li>
    <li>Microenvironmental and immune evasion mechanisms—including HLA LOH, B2M inactivation, NLRC5 disruption, promoter methylation of neoantigens, high PD-L1/PD-1 pathway activation, metabolic and immunosuppressive stromal/innate immune states—are recurrent in subsets of LUADs, especially with high subclonal neoantigen burden. <a href="../results/extraction-result-108.html#e108.0" class="evidence-link">[e108.0]</a> <a href="../results/extraction-result-108.html#e108.1" class="evidence-link">[e108.1]</a> <a href="../results/extraction-result-108.html#e108.2" class="evidence-link">[e108.2]</a> <a href="../results/extraction-result-38.html#e38.7" class="evidence-link">[e38.7]</a> <a href="../results/extraction-result-108.html#e108.3" class="evidence-link">[e108.3]</a> <a href="../results/extraction-result-108.html#e108.4" class="evidence-link">[e108.4]</a> <a href="../results/extraction-result-38.html#e38.9" class="evidence-link">[e38.9]</a> <a href="../results/extraction-result-45.html#e45.4" class="evidence-link">[e45.4]</a> <a href="../results/extraction-result-45.html#e45.3" class="evidence-link">[e45.3]</a> <a href="../results/extraction-result-38.html#e38.10" class="evidence-link">[e38.10]</a> <a href="../results/extraction-result-39.html#e39.9" class="evidence-link">[e39.9]</a> </li>
    <li>Cases exist where no plausible driver is found even after comprehensive sequencing and omics analysis ('pan-negative', 'orphan' driver cases), suggesting existance of as-yet uncharacterized or cryptic driver mechanisms. <a href="../results/extraction-result-32.html#e32.0" class="evidence-link">[e32.0]</a> <a href="../results/extraction-result-37.html#e37.5" class="evidence-link">[e37.5]</a> <a href="../results/extraction-result-114.html#e114.3" class="evidence-link">[e114.3]</a> </li>
    <li>Sampling bias and intra-tumoral heterogeneity may artifactually render tumors 'driver negative' where canonical drivers are present in un-sampled subclones. <a href="../results/extraction-result-43.html#e43.10" class="evidence-link">[e43.10]</a> <a href="../results/extraction-result-35.html#e35.7" class="evidence-link">[e35.7]</a> </li>
    <li>Integration of multi-omic analyses (TCGA, Collisson et al., Chen et al.) consistently reveals a collection of alternative alterations (genetic, epigenetic, expression-based, structural, and post-transcriptional) in non-canonical drivers. <a href="../results/extraction-result-44.html#e44.0" class="evidence-link">[e44.0]</a> <a href="../results/extraction-result-33.html#e33.0" class="evidence-link">[e33.0]</a> <a href="../results/extraction-result-31.html#e31.2" class="evidence-link">[e31.2]</a> <a href="../results/extraction-result-39.html#e39.10" class="evidence-link">[e39.10]</a> <a href="../results/extraction-result-44.html#e44.5" class="evidence-link">[e44.5]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> The theory synthesizes extensive evidence across multiple studies into a formally compensatory, modular framework that is more comprehensive than existing models, qualifying as 'somewhat-related-to-existing'.</p>            <p><strong>What Already Exists:</strong> Individual alternative drivers, epigenetic alterations, and immune/microenvironmental contributors have each been separately cataloged, as has the observation of pan-negative or rare/orphan cases.</p>            <p><strong>What is Novel:</strong> The explicit integration of all four axes (genetic, epigenetic, mutational process, and microenvironmental/immune) as modular, functionally compensatory modules for sustaining oncogenesis in RTK/RAS/RAF-negative LUAD, with recognition of their possible additivity or mutual exclusivity, is a conceptual advance.</p>
        <p><strong>References:</strong> <ul>
    <li>Collisson EA et al. (2014) Comprehensive molecular profiling of lung adenocarcinoma [Catalogs alternative drivers and subtypes but does not present a unified compensatory model]</li>
    <li>Campbell JD et al. (2016) The somatic genomic landscape of lung cancer [Patterns individual drivers and processes but lacks an integrated theory]</li>
    <li>Chen L et al. (2016) Identification of novel candidate drivers... [Computational multi-omic nomination but not as modular compensation]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Endogenous and Exogenous Mutational Processes Fuel Subclonal Diversification and Late Driver Emergence in Absence of Dominant Canonical Drivers</h3>
            <p><strong>Statement:</strong> In LUADs lacking truncal/early RTK/RAS/RAF pathway drivers, persistent endogenous mutational processes (APOBEC cytidine deaminase activity, 5-methylcytosine deamination, chromosomal instability, inefficient DNA repair by TDG/MBD4), as well as any continuing exogenous exposures (e.g., tobacco), result in high subclonal heterogeneity. This heterogeneity facilitates the late acquisition of regionally private driver mutations, structural variations, or splicing events, and creates substrates for immune selection (such as neoantigen-driven HLA LOH).</p>
            <p><strong>Domain/Scope:</strong> Applies to human lung adenocarcinomas lacking early/truncal canonical RTK/RAS/RAF pathway driver mutations, especially where elevated mutational burden or complex subclonal architecture is observed regardless of smoking status.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>In tumors with a strong early environmental (smoking) signature, C>A transversions may dominate the clonal (trunk) landscape and endogenous processes dominate subclonal branches.</li>
                <li>Some never-smoker LUADs display low overall mutation burden and correspondingly fewer subclonal diversifications.</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>APOBEC-associated C>T and C>G mutations are significantly enriched in subclonal/late mutations, leading to branch-specific acquisition of driver mutations (e.g., PIK3CA, TGFBR1, EP300, PTPRD, AKAP9) and elevated subclonal neoantigen burden. <a href="../results/extraction-result-112.html#e112.0" class="evidence-link">[e112.0]</a> <a href="../results/extraction-result-38.html#e38.4" class="evidence-link">[e38.4]</a> <a href="../results/extraction-result-41.html#e41.3" class="evidence-link">[e41.3]</a> <a href="../results/extraction-result-41.html#e41.9" class="evidence-link">[e41.9]</a> <a href="../results/extraction-result-108.html#e108.1" class="evidence-link">[e108.1]</a> <a href="../results/extraction-result-112.html#e112.5" class="evidence-link">[e112.5]</a> </li>
    <li>TDG expression negatively correlates with C->T mutation load; inefficient repair of methyl-cytosine deamination fuels endogenous mutational signatures, especially in driver-negative tumors. <a href="../results/extraction-result-41.html#e41.5" class="evidence-link">[e41.5]</a> </li>
    <li>Chromosomal instability and genome doubling are temporally mapped to precede regional diversification, providing substrate for copy-number–based subclonal driver events, and correlate with high subclonal heterogeneity. <a href="../results/extraction-result-38.html#e38.5" class="evidence-link">[e38.5]</a> <a href="../results/extraction-result-112.html#e112.1" class="evidence-link">[e112.1]</a> </li>
    <li>Subclonal branches with high neoantigen burden show selection for HLA LOH and other immune escape mechanisms, indicating that the immunogenetic landscape is a consequence of ongoing subclonal diversification. <a href="../results/extraction-result-108.html#e108.1" class="evidence-link">[e108.1]</a> <a href="../results/extraction-result-108.html#e108.5" class="evidence-link">[e108.5]</a> <a href="../results/extraction-result-38.html#e38.7" class="evidence-link">[e38.7]</a> </li>
    <li>Exogenous tobacco signature (C>A) is prominent in trunk mutations of smokers, but recedes in importance in later subclonal evolution, indicating a temporal shift to endogenous processes as the tumor evolves; such processes dominate in never-smokers from the onset. <a href="../results/extraction-result-41.html#e41.6" class="evidence-link">[e41.6]</a> <a href="../results/extraction-result-112.html#e112.6" class="evidence-link">[e112.6]</a> <a href="../results/extraction-result-112.html#e112.0" class="evidence-link">[e112.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> Endogenous mutagenesis has been described for subclonal diversification, but its positioning as a compensatory axis and necessary progression logic in classical driver-negative tumors is new.</p>            <p><strong>What Already Exists:</strong> The role of endogenous processes—APOBEC, methyl-cytosine deamination, CIN—and exogenous mutagens (smoking) in creating subclonal diversity and mutational signatures is established.</p>            <p><strong>What is Novel:</strong> Their necessity as ongoing, obligatory processes to fuel late driver emergence, subclonal adaptation, and immune escape specifically in the context of canonical driver-negative LUAD, is a novel level of mechanistic synthesis.</p>
        <p><strong>References:</strong> <ul>
    <li>Jamal-Hanjani M et al. (2017) Tracking the Evolution of NSCLC [Highlights APOBEC in subclonal evolution but not as a compensatory process for driver-negativity]</li>
    <li>Alexandrov LB et al. (2013) Signatures of mutational processes in human cancer [Describes mutation signatures without a compensatory framework]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Systematic multi-omic profiling of large driver-negative LUAD cohorts will consistently uncover rare/alternative oncogenic fusions, mutations of genes such as MGA, ZKSCAN1, NF1, RIT1, MET exon 14 skipping, and significant copy-number alterations, at frequencies surpassing those in canonical-driver positive tumors.</li>
                <li>Driver-negative tumors will display a higher prevalence of epigenetic reprogramming (CIMP-high methylator phenotype, chromatin modifier/spliceosome mutations), methylation or expression blocks not explained by CNAs, and/or increased activity of endogenous mutational processes (APOBEC signatures, subclonal copy-number diversity) compared to canonical driver-positive cases.</li>
                <li>A higher fraction of driver-negative LUADs will show evidence of active or adaptive immune escape strategies (e.g., HLA LOH, B2M mutation, neoantigen promoter methylation) and higher subclonal or spatially restricted neoantigen burden when compared to driver-positive LUADs.</li>
                <li>Integrated proteomic and transcriptomic analyses will reveal that classical oncogenic signaling outputs (e.g., mTOR, WNT, PI3K/AKT, MAPK pathway activation signatures) are present in driver-negative tumors but derive from alternative, modular upstream processes.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Highly multiplexed single-cell genotyping and spatial transcriptomics of pan-negative LUADs will identify cryptic, highly focal or low-frequency novel drivers (e.g., undiscovered kinase fusions, structural variants, complex chromoanagenesis), or reveal convergent evolutionary trajectories at the network or pathway level despite diverse genetic origins.</li>
                <li>Targeted therapy directed at epigenetic machinery (demethylating agents, bromodomain inhibitors) or immune-escape targets (e.g., restoration of HLA-I, neoantigen vaccination, HLA-restricted T-cell therapies) will produce objective clinical responses in a subset of classical driver-negative LUAD patients.</li>
                <li>Combined inhibition of compensatory paracrine signaling axes (e.g., FGFR/FGF axis, microenvironmental signals) and curtailment of ongoing endogenous mutagenic activity (e.g., APOBEC inhibition) will result in reduced subclonal acquisition of new drivers and impede tumor progression.</li>
                <li>Germline variant analysis in driver-negative LUADs may reveal novel host-susceptibility loci or polygenic backgrounds that alter the likelihood of compensatory oncogenesis through alternative axes.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If comprehensive multi-omic (DNA, RNA, methylome, proteome, chromosomal and single-cell) profiling in classical driver-negative LUADs frequently fails to reveal any plausible alternative oncogenic events, the compensatory theory is refuted.</li>
                <li>If driver-negative LUADs uniformly respond to RTK/RAS/RAF pathway–targeted therapies at rates similar to driver-positive tumors, undermining the necessity of compensatory mechanisms, the theory would be challenged.</li>
                <li>If the extent of subclonal mutational and epigenetic heterogeneity in driver-negative tumors is not increased or is actually decreased compared with canonical driver-positive tumors, the assertion that endogenous mutational process compensation is required would be called into question.</li>
                <li>If analysis of proteomic activation signatures reveals a consistent lack of canonical oncogenic signaling in driver-negative tumors, the compensatory functional output model would require significant revision.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>A minority of cases remain pan-negative even after multi-omic and fusion profiling, suggesting the existence of as-yet-undiscovered driver mechanisms or technical limitations. <a href="../results/extraction-result-32.html#e32.0" class="evidence-link">[e32.0]</a> <a href="../results/extraction-result-37.html#e37.5" class="evidence-link">[e37.5]</a> <a href="../results/extraction-result-114.html#e114.3" class="evidence-link">[e114.3]</a> </li>
    <li>Occasional coexistence of two or more alternative mechanisms in single tumors (e.g., epigenetic and microenvironmental or multiple rare genetic alterations) is not fully specified in the compensatory modularity model. <a href="../results/extraction-result-41.html#e41.0" class="evidence-link">[e41.0]</a> <a href="../results/extraction-result-36.html#e36.2" class="evidence-link">[e36.2]</a> <a href="../results/extraction-result-108.html#e108.1" class="evidence-link">[e108.1]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>